A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess Efficacy and Safety of Reparixin in Cancer Related Fatigue in Pts With Advanced / Metastatic Breast Cancer Undergoing Taxane-based Chemotherapy

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 02 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Reparixin (Primary) ; Docetaxel; Paclitaxel
Indications Advanced breast cancer; Fatigue; HER2 negative breast cancer; Male breast cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Dompe Farmaceutici

Most Recent Events

26 Jan 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
19 Jan 2023 Status changed from recruiting to withdrawn prior to enrolment.
26 Sep 2022 The trial has been discontinued in Germany, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight